Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
